IngredientesMucins are a family of high-molecular-weight glycoproteins that serve as the principal structural and functional components of mucus across virtually all mucosal surfaces in the animal body. Mucins are currently defined as high-molecular-weight glycoproteins that contain at least one and sometimes multiple protein domains that are sites of extensive O-glycan attachment (mucin-like domains). Mucin is a glycoprotein that is the main component responsible for the viscous and elastic gel-like properties of mucus.
Mucins are large glycoproteins that are ubiquitous in the animal kingdom. They coat the surfaces of many cell types and can be secreted to form mucus gels that assume important physiological roles in many animals.
These polydisperse glycoproteins (ranging from 250,000 to 20,000,000 daltons) are approximately 80% carbohydrate on a mass basis and have a high intrinsic viscosity due to their large size and extreme hydrophilicity. Mucin oligosaccharides, the structures responsible for this hydrophilicity, are heterogeneous in size and structure but are chiefly O-linked, initiating from N-acetylgalactosamine residues attached to threonine and serine residues of the polypeptide backbone.
The mucin family is highly glycosylated, and the molecular weight of these glycoproteins is typically around 200 kDa to more than 1,000 kDa. The glycoproteins contain three domains: an N-terminal domain, a C-terminal domain, and in the middle, tandem repeats. A repeating sequence of peptide chains rich in threonine, serine, and proline (PTS domains) is frequently found in mucin domains, called tandem repeats.
The dense glycosylation of mucins confers a relatively extended conformation to the molecule, which can associate into large oligomers in the tens of megadaltons via disulfide bonds and other weaker interactions.
Epithelial mucins, MUC gene products, are widely expressed in human organs such as airways, the urogenital and gastrointestinal tracts, and the eyes. MUC-type mucins have very large sizes and complex structures with very extensive O-glycosylation and are regarded as protective molecules.
The mucin family includes a total of twenty family members and is divided into two classes: the secreted mucins (both gel-forming and non-gel-forming) and the membrane-bound mucins. In humans, 7 members in the family of the secreted mucins have been identified, which can be further subdivided into gel-forming mucins (MUC2, MUC5AC, MUC5B, MUC6, MUC19) and non-gel-forming mucins (MUC7, MUC8). The membrane-associated mucins count 11 members (MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, MUC20, and MUC21).
MUC genes are differentially expressed in goblet cells in diverse epithelial tissues. MUC5AC is the predominant mucin normally expressed in goblet cells in the lung, eyes, and stomach, while MUC2 is expressed in intestinal goblet cells. MUC5B and MUC19 mucins are typically restricted to glandular cells.
Mucins are endogenously produced throughout the human body, but for supplemental and research purposes, mucins are extracted from several natural animal sources:
PGM has been used in a wide range of supplements, personal hygiene products, and lubricants, as well as in artificial saliva, due to its promising antiviral activity, biocompatibility, and availability.
Commercially available forms include:
It is important to note that commercially available porcine gastric mucins (such as Sigma Type II and III) lack key native functional properties such as gel formation and friction reduction; a robust purification process for functional mucins from porcine tissue is necessary to preserve these characteristics.
Because mucin as a defined biochemical entity was only characterized in the late 19th and early 20th centuries, formal ethnobotanical or ethnomedicinal records refer to mucin-rich preparations rather than isolated mucin itself.
The use of snail slime — a mucin-rich secretion — as a healing agent appears in several ancient traditions. In classical Greek medicine, Pliny the Elder's Naturalis Historia (1st century CE) documented the use of snail preparations for skin ailments, coughs, and stomach disorders, though these ancient references describe the whole snail secretion and not isolated mucin glycoproteins. The practice of applying snail secretions to burns, wounds, and irritated skin has been documented in folk medicine traditions around the Mediterranean, the Andes in Chile, and North Africa, where Helix aspersa snails were readily available. In Chilean folk medicine, snail mucus has been used topically for scar healing and wound closure.
In many traditional Asian medicinal systems, preparations from pig or bovine stomach lining were used to address gastrointestinal ailments, including dyspepsia, gastric ulcers, and diarrhea. These preparations, consumed as broths or concentrated extracts, would have naturally contained high concentrations of mucin glycoproteins from the gastric mucosa, though the active role of mucin was not recognized at the time.
Evidence is limited as to whether licorice root may help increase the natural production of mucins, but it has been used as a natural gut remedy for centuries. Traditional herbalism in European, Chinese, and Ayurvedic traditions long employed licorice (Glycyrrhiza glabra) as a demulcent and gastroprotective agent, an action that modern research has tentatively associated in part with the upregulation of endogenous mucin expression.
Plant mucilages — polysaccharide-based gels produced by slippery elm (Ulmus rubra), marshmallow root (Althaea officinalis), aloe vera, and okra — were historically used as demulcents to soothe and protect mucous membranes in the mouth, throat, esophagus, and gut. Though chemically distinct from mucin glycoproteins, these substances were functionally employed to perform analogous roles: coating, lubricating, and protecting mucosal surfaces. It is critical to note that plant mucilages are not biologically equivalent to animal-derived mucin.
Mucin is defined as a highly polymerized peptide with densely clustered O-glycan chains, where threonine or serine residues in the peptide connect with the anomeric carbon of the first saccharide (normally N-acetylgalactosamine: GalNAc), forming an ether bond.
The mucin family is composed of glycoproteins that contain a protein backbone conjugated with a large number of O-linked oligosaccharide chains and a few N-glycan chains. The composition of these glycoproteins is dominated by carbohydrate, which can total in some cases as much as 80% of the weight of the molecule.
There appear to be two major types of mucin: one thought to be monomeric and primarily located at the cell surface, and the other oligomeric. This latter type is secreted and thought to be responsible for the rheological properties of mucus.
Solutions of porcine gastric mucins are excellent lubricants, especially in the boundary lubrication and mixed lubrication regime. These low friction values are suggested to originate from hydration lubrication: mucins adsorb very well on hydrophobic surfaces and form thin surface layers, where the oligosaccharide side-chains on the mucin backbone bind water. During the application of shear forces, energy is dissipated by moving the water molecules in this mucin layer, leading to strongly reduced friction.
The association of the intestinal mucus layer with antimicrobial peptides (AMPs) constitutes the body's first line of defence against bacterial infections. The antimicrobial spectrum of AMPs is broad, ranging from antifungal and antibacterial to antiviral activity. AMPs are strongly colocalized with mucus, with tens of antimicrobial peptides found in the colonic mucus extracts of healthy individuals and mice.
Considering the limited number of species that can degrade the complex mucin structure and the described health effects conferred by its degradation, mucins fit the definition of prebiotic substances — "substrates that are selectively utilized by host microorganisms conferring a health benefit." Mucin glycans constitute 80% of the dry weight of the mucus layer covering the intestinal epithelium and are present in the luminal content as a consequence of continuous mucus desquamation, such that the human body has even been described as producing its own prebiotic.
Mucins form part of the dynamic, interactive mucosal defensive system active at the mucosal surface of the gastrointestinal tract. They are carbohydrate-rich glycoproteins with unique molecular structure and chemical properties. They cover all mucosal surfaces and play an important protective role as they form a physical, chemical, and immunological barrier between the environment and the organism.
Mucins are the gatekeepers of the mucosal barrier of the gastrointestinal tract and are aberrantly expressed in various gastrointestinal pathologies, including pathogen infection, inflammation, and uncontrolled growth and spread of abnormal cells.
The intestinal barrier, which primarily consists of a mucus layer, an epithelial barrier, and a gut vascular barrier, has a crucial role in health and disease by facilitating nutrient absorption and preventing the entry of pathogens. The intestinal barrier is in close contact with gut microbiota on its luminal side and with enteric neurons and glial cells on its tissue side.
An increasing number of protective proteins have been identified that appear in the adherent mucus layer at the mucosal surface. These proteins are co-secreted with mucins in some cases, interact with mucins at a molecular level through peptide and carbohydrate sites, or benefit from the viscoelastic aqueous environment afforded by the mucus gel. The mechanism of many of these interactions remains to be elucidated but is clearly part of an integrated innate and adaptive mucosal defensive system relying on the mucins as an integral component to provide a mucus gel.
The gastrointestinal mucus, mostly composed of mucin glycoproteins, covers the epithelium and plays an essential role in digestive and barrier functions. Certain bacteria have developed various enzymatic machinery that can cleave and catabolize the sugar moieties for colonization. The fucosidase and sialidase activity of certain symbiotic bacteria, such as Bacteroides thetaiotaomicron, can liberate mucosal glycans without compromising the integrity of the mucus layer to support colonization.
Host-derived mucus glycans on gut-secreted mucin proteins serve as a continuous endogenous source of microbiota-accessible carbohydrates (MACs) for resident microbes.
Mucins are glycoproteins that are an integral part of the immune system, acting as a physical barrier for epithelial cells against pathogens and foreign invaders and helping prevent inflammatory responses. They also act as lubrication in gel-like secretions such as saliva, mucus, and tear film over the eyes. Roughly 70% of the immune system resides within the GI tract.
Preclinical (Animal/In Vitro) Evidence:
In a mouse model study, researchers liberated and purified O-linked glycans from porcine gastric mucin and assessed their efficacy in shaping the recovery of a perturbed microbiota. They found that porcine mucin glycans (PMGs) and human milk oligosaccharides (HMOs) enrich for taxonomically similar resident microbes, and PMGs aid recovery of the microbiota after antibiotic treatment, suppress Clostridium difficile abundance, and delay the onset of diet-induced obesity. This is animal-model evidence only; the results have not been replicated in controlled human trials.
MUC2 mucin is an important secretory protein found in the human gut. Recent studies indicated that MUC2 mucin plays a role in the protection of the gut barrier, the regulation of microbiome homeostasis, and the prevention of diseases.
Characterization of Evidence: While the use of mucin in topical formulations is well-supported, evidence for oral mucin supplementation directly improving mucus membrane health systemically is limited and less robust. Most benefits are seen with localized application rather than systemic ingestion.
Clinical Observational Evidence:
The mucus layer in the gastrointestinal tract plays an important role in host innate defense, regulation of secretion, and absorption processes, maintaining colonization resistance, which composes the integrity of the protective mucus barrier in the large intestine. Investigations of mucin expression in the colon mucosa can improve the understanding of the protective function of the mucosal barrier in ulcerative colitis (UC) and Crohn's disease (CD).
A clinical study of 77 patients with UC and CD (the expression of mucin MUC2, MUC3, MUC4, and TFF3 correlated with the activity of disease and the extent of the inflammatory process in the large intestine; the most pronounced alteration of mucin expression was observed in patients with severe UC and CD).
Overall, mucin expression was found to be abnormal in UC. Derangements in MUC1, MUC4, and MUC5B were detected both at onset and after treatment; MUC2 and MUC13 were unaffected.
Altered mucin production is able to weaken the mucus barrier, triggering an immune response and predisposing to UC onset. The finding of mucin depletion in mucosal samples from UC patients points toward perturbations in mucin production. Impairment of MUC2 expression has been reported to be a major cause of mucosal injury in IBD.
Therapy that enhances or restores mucin expression has not been proposed to date. Mucin enhancement could provide long-lasting symptomatic control of UC by counteracting the weakness of the mucosal barrier. Since mucin expression abnormalities are thought to be the earliest cause of UC, mucin restoration should not be excluded from the definition of mucosal healing.
Characterization of Evidence: Current evidence for IBD is observational and mechanistic (biopsy and molecular profiling studies), not interventional. No large randomized controlled trials of exogenous oral mucin supplementation for IBD in humans have been published to date.
Clinical Evidence (strongest area for mucin preparations):
Dry mouth, also known as xerostomia, is a condition in which insufficient or ineffective saliva does not provide sufficient oral lubrication. The severity can vary from a mild discomfort to a debilitating condition. Xerostomia arises as a side effect of various medications, diseases, radiation therapy, chemotherapy, or nerve damage.
Artificial saliva containing polyacrylic acid, carboxymethyl cellulose, and porcine gastric mucins, which especially mimics the viscous properties of saliva, can be considered for mouth lubrication.
A controlled clinical study by Vissink et al. (1987) enrolled thirty-nine patients with xerostomia who filled out a questionnaire before application of the mucin-containing artificial saliva (applied by spray) and after six weeks of usage. The application of the mucin-containing saliva substitute reduced the sensation of a dry mouth and improved oral functions such as chewing, swallowing, and speech; patients also felt less restricted in their social activities.
Many authors have analyzed literature data on clinical and laboratory tests of saliva substitutes. The results indicate that in patients with xerostomia (mainly after radiotherapy), commercially available saliva preparations seem to significantly reduce the symptoms of dry mouth.
In general, mucin-based substitutes seem to be better than preparations based on carboxymethylcellulose due to rheological and lubricating properties. However, porcine gastric mucins used as a substitute for salivary mucins have very low viscoelastic properties compared to native human saliva.
Both saliva flow and level of Mucin 5B decrease in OLP patients. Since Mucin 5B is effective for wetting and lubrication of the oral cavity, this result can suggest a possible reason for mouth dryness in OLP patients.
Characterization of Evidence: The use of mucin in artificial saliva preparations has the most robust clinical evidence among all applications for exogenous mucin. Multiple clinical trials support symptomatic efficacy for xerostomia. Mucin-based preparations are recommended as a first-line symptomatic treatment in several clinical guidelines for radiation-induced dry mouth.
In Vitro and Animal Evidence:
Since its discovery, Akkermansia muciniphila has gained attention in scientific studies, as its abundance is inversely correlated with disorders such as inflammatory bowel disease, obesity, and autism. In contrast to mucin treatment, the addition of A. muciniphila hardly affected the community in vitro. Prebiotic treatments such as mucin generally induce more significant changes in community composition compared to probiotic treatments.
Results from gut microbiota studies showed that gut commensals having mucin-degrading ability were widely distributed in the gut microbiota and were more abundant than previously thought. Many previously uncharacterized mucin degraders were isolated from fecal samples, suggesting these mucin-degrading gut commensals were underappreciated. These findings indicate that mucin-degrading gut commensals were widely distributed and showed anti-inflammatory effects against pathogen infection and potential in modulating the epithelial barrier function.
Characterization of Evidence: This area is predominantly characterized by in vitro fermentation studies, mouse models, and microbiome observational studies. Direct oral mucin supplementation for the purpose of gut microbiome modulation in humans has not been assessed in any registered randomized controlled trial as of the present writing.
Preclinical Evidence:
Purified porcine gastric mucin (PGM) is an alternative biomaterial to native mucin which displays multifunctional properties for exploring biomedical applications. One study evaluated the in vitro (RAW 264.7 macrophage cells) and in vivo (zebrafish embryos and larvae) bioactivities of PGM. The LC50 of PGM was 197.9 µg/mL for embryos, while it was non-toxic to RAW 264.7 cells even at 500 µg/mL.
Protective effects of PGM from pathogenic Aeromonas hydrophila were demonstrated by high larvae survival rates of 85.0% and 94.0% at 50 and 100 µg/mL of PGM exposure, respectively. Heat tolerance effect of PGM at 50 and 100 µg/mL on larvae was confirmed by 75% and 100% survival rates, respectively.
Antiviral Properties: The antiviral properties of PGM have been discussed and make this glycoprotein attractive for application in the medical field. In vitro studies have described mucin biopolymers as broad-spectrum antiviral agents; however, these findings are not yet translated into clinical human trials of oral mucin supplementation.
Characterization of Evidence: Immunomodulatory and antiviral evidence for PGM is at the preclinical (in vitro and zebrafish/animal model) stage only. To the best of the researchers' knowledge at the time, there has been no study to explore the effect of exogenous PGM as a modulator of innate immune responses in human clinical trials.
Animal Evidence:
One study investigated the photoprotective effect of snail mucin against ultraviolet B (UVB)-induced skin photoaging in an animal model. SKH-1 hairless male mice were fed with snail mucin or vehicle for 14 weeks with UVB exposure, and skin damage was analyzed by skin replicas, epidermal thickness, collagen fiber integrity, and moisture contents in the dermal tissue. The results showed that the depth of wrinkles, relative moisture content, and relative elasticity induced by UVB irradiation on the epidermis of mice were improved by supplementation of snail mucin.
Characterization of Evidence: Animal model only; no controlled human clinical trials on oral snail mucin supplementation for skin aging have been published in peer-reviewed literature.
Akkermansia muciniphila is a bacterium that lives in the intestinal mucus layer and uses mucin as a primary carbon and nitrogen source. It deserves mention because supplements containing this organism are sometimes marketed alongside mucin, and the bacteria's activity is directly dependent on host mucin availability.
Akkermansia muciniphila plays a beneficial role in various diseases including diabetes, obesity, aging, cancer, and metabolic syndrome, and is gaining popularity as a regulator that influences the intestinal flora and intestinal barrier, recognized as a "new generation of probiotics."
Regarding human clinical evidence: among all related 15 studies testing the effects of A. muciniphila, only one study was conducted in humans, evaluating the safety, tolerability, and metabolic parameters of A. muciniphila (BAA-835) supplementation either in live or pasteurized form for 3 months compared with placebo in 40 volunteers with insulin resistance who had overweight or obesity. Pasteurized A. muciniphila improved insulin sensitivity; however, live A. muciniphila supplementation only showed mild metabolic improvements with most parameters showing borderline significance.
Respiratory tract mucin genes and mucin glycoproteins in health and disease have been reviewed in detail in the physiological literature. In the lower respiratory tract, expression of at least 12 human mucin genes (MUC1, MUC2, MUC4, MUC5AC, MUC5B, MUC7, MUC8, MUC11, MUC13, MUC15, MUC19, and MUC20) have been observed at the mRNA level in tissues from healthy individuals.
Mucin deficiency and hypersecretion are both implicated in respiratory diseases such as asthma, COPD, and cystic fibrosis; however, no clinical evidence supports oral exogenous mucin supplementation for respiratory conditions. Treatment strategies in this domain focus on mucolytics (to reduce hypersecretion) rather than supplementation.
Exogenous mucin preparations are used in several formats; the following dosages are reported in scientific literature only:
It is important to acknowledge that no standardized, clinically validated oral dosage regimen for exogenous mucin as a dietary supplement exists in the peer-reviewed literature. The dosages cited in supplement marketing (typically 500–1,500 mg/day) lack rigorous clinical trial support establishing efficacy or optimal dosing in human subjects.
Short-term studies show good safety, but long-term data are lacking. Mucin glycoproteins are endogenous human molecules and are consumed daily via foods containing mucin-rich tissues (tripe, stomach, intestinal preparations), suggesting a generally favorable tolerability profile when administered orally.
Studies have reported cell toxicity effects during cell culture experiments, and inferior effects on virus inhibition upon reconstituted commercial mucin treatments. Commercially available mucins such as PGM Type II and III (Sigma-Aldrich) lack key native functional properties, as has been shown previously; even cell toxicity was observed for some commercial PGMs. This highlights that the quality of mucin purification is a critical safety and efficacy consideration.
Porcine-derived mucin preparations carry potential allergenicity concerns for individuals with pork allergies. They are also unsuitable for vegetarians, vegans, and individuals whose dietary laws prohibit porcine or non-halal/non-kosher animal products. Fish-derived mucin preparations may carry risk for individuals with fish or shellfish allergies.
Since mucin is extracted from animal slaughterhouse tissue, theoretically there is a risk of contamination with zoonotic pathogens if purification standards are not maintained. Most animal studies with A. muciniphila supplementation were performed with A. muciniphila grown under mucin-containing conditions. The animal-derived mucin may introduce contaminants and cause compromised beneficial effects.
Because mucin glycans serve as substrates for gut bacteria, exogenous supplementation with mucin may selectively amplify mucin-degrading species in the gut. Total RNA sequencing in one study revealed major transcriptional changes of Bacillus cereus upon incubation with porcine gastric mucin (PGM), comprising genes encoding enterotoxins and putative virulence factors. PGM was partially degraded by B. cereus via secreted proteases, and the amount of enterotoxins detectable in culture media supplemented with PGM was clearly increased. This finding is from a laboratory model and its clinical relevance to dietary supplementation is unknown, but it suggests that mucin could, in some contexts, serve as a growth substrate for pathogenic bacteria.
As a dietary supplement, mucin is not subject to the pre-market approval requirements applied to pharmaceutical drugs in most jurisdictions (including the United States under DSHEA, and the EU). Quality, purity, and potency can therefore vary considerably between manufacturers. Mucin is not regulated as strictly as pharmaceuticals; quality varies widely.
No well-documented pharmacokinetic or pharmacodynamic drug interactions with exogenous oral mucin supplementation have been identified in peer-reviewed literature as of the current date. Due to mucin's potential to alter gut permeability and mucosal barrier function, theoretical interactions with oral drug absorption, particularly for drugs that rely on mucosal uptake, cannot be excluded but have not been formally characterized in human studies.
Deregulated mucin expression is a hallmark of several inflammatory and malignant pathologies. Emerging evidence suggests that, apart from as biomarkers, these deregulated mucins are functional contributors to pathogenesis in inflammation and cancer. Both overexpression and downregulation of mucins in various organ systems is associated with pathobiology of inflammation and cancer. Restoration of mucin homeostasis has become an important goal for therapy and management of such disorders, fueling the quest for selective mucomodulators.
The growing understanding of the structure and function of mucin molecules and their functionalities has sparked interest in investigating the use of mucins as building blocks for innovative functional biomaterials. These pioneering studies have explored how new biomaterials can benefit from the barrier properties, hydration and lubrication properties, unique chemical diversity, and bioactivities of mucins.
Research into recombinant and synthetic mucin-mimetics — engineered molecules designed to replicate mucin's functional properties without reliance on animal slaughterhouse material — represents an active and growing field, though no such products have yet reached widespread commercial distribution as supplements.
Mounting evidence now suggests that the intestinal barrier is compromised not only in digestive disorders, but also in disorders of the central nervous system (CNS), such as Parkinson's disease, autism spectrum disorder, depression, multiple sclerosis, and Alzheimer's disease, positioning mucin biology at the intersection of gastroenterology and neuroscience. Whether mucin supplementation could have any relevance in this context remains entirely speculative and uninvestigated in clinical trials.
Condiciones de salud que Mucina puede ayudar a apoyar.
Salivary and esophageal mucins form a mucus-bicarbonate barrier that retards hydrogen ion diffusion and protects the esophageal mucosa from acid damage. Clinical research has shown that patients with reflux esophagitis have impaired esophageal mucin secretion compared to healthy controls. Stimulating mucin production is recognized as a therapeutic target in GERD management.
Mucin barrier defects—particularly altered MUC2 expression and goblet cell dysfunction—are well-documented in both ulcerative colitis (UC) and Crohn's disease in human biopsy studies. Muc2-deficient mice spontaneously develop colitis, establishing a causal mechanistic link. Clinical studies show that mucin expression profiles are abnormal in UC at disease onset and after treatment.
Mucin deficiency on the ocular surface is a recognized driver of dry eye disease (DED), and pharmacological agents that stimulate mucin secretion (mucin secretagogues) are clinically proven treatments. Randomized controlled trials demonstrate that mucin secretagogue eye drops (diquafosol, rebamipide) significantly improve corneal staining, tear breakup time, and symptom scores. Alterations in both cell surface-associated and gel-forming mucins occur in dry-eye-related ocular surface diseases.
Animal (porcine gastric) mucin is used in saliva substitute formulations such as Saliva Orthana for xerostomia. An objective tribological study found mucin-containing substitutes were among only a few biopolymers outperforming water in oral lubrication by adsorbing to the salivary conditioning film, closely mimicking native salivary mucin boundary lubrication.
Mucin composition changes dramatically across the spectrum of gastric disease from superficial gastritis to gastric cancer, as documented in large clinical biopsy studies. The gastric mucin layer protects the mucosa from acid, pepsin, and external injury. Disruption of mucin phenotype is directly linked to disease progression.
Mucin glycans serve as a selective nutritional substrate for specific gut bacteria, meeting the formal definition of a prebiotic. In vitro and preclinical research shows mucin supplementation reshapes microbial composition, enriching beneficial Lactobacillus species and promoting polyamine production that supports epithelial barrier function. The human body's continuous mucus desquamation has been described as producing its own prebiotic.
Mucin barrier dysfunction—including altered goblet cell secretion and MUC2 structural changes—is a hallmark of IBD pathogenesis documented in clinical and experimental studies. IBD patients display defects in mucus layer composition that contribute to increased intestinal permeability and chronic inflammation. Changes in intestinal permeability correlate clinically with IBD disease course.
Mucin deficiency, particularly loss of MUC2, is mechanistically linked to increased intestinal permeability ('leaky gut'). Muc2 knockout mice develop intercellular junction defects and colitis, demonstrating that mucin is necessary for barrier integrity. Clinical studies in IBD patients document the co-occurrence of mucin layer abnormalities and increased gut permeability.
Mucins are the primary macromolecular components responsible for the viscoelastic and gel-forming properties of mucus throughout the body, including airways and the gastrointestinal tract. Aberrant mucin secretion and accumulation are clinical hallmarks of chronic respiratory diseases including COPD, asthma, and cystic fibrosis. Regulation of mucin gene expression is a major research and therapeutic target.
Salivary mucins coat and lubricate the pharyngeal and oral mucosa, providing protection against desiccation, mechanical insult, and microbial colonization. Reduced salivary mucin is associated with increased vulnerability to oral mucosal damage and infection. The protective lubricating function of mucin on throat mucosa is well-documented in the oral biology literature.
Mucin forms a critical component of the gastric mucus-bicarbonate barrier that protects the gastric and duodenal epithelium from acid-peptic damage. Animal studies using snail-derived mucin (Cornu aspersum) demonstrate direct gastroprotective and anti-inflammatory effects against NSAID-induced ulcers. Pharmacological enhancement of mucin production is a recognized mechanism of antiulcer drugs.
Sistemas corporales que Mucina puede ayudar a apoyar.
Volver